The Severe Chronic Neutropenia International Registry (the Registry) opened in 1994 to study the long-term safety and efficacy of granulocyte-colony stimulating factor (G-CSF) treatment for patients with congenital, cyclic and idiopathic neutropenia. The Registry initially evaluated hematological parameters, growth and development, consequence of pregnancy, and other important clinical events. The Registry is now an international research organization based at the University of Washington. In this grant, we request funding to continue the work of the Registry. In brief, the specific aims are: (1) To expand the longitudinal clinical database on patients with severe chronic neutropenia, (2) To expand a bank of biological materials to support genetic and molecular research and study the evolution of patients at risk to develop myelodysplasia and leukemia, (3) To serve as a resource to support clinical trials to improve therapy, (4) To serve as a educational resource for patients, families, physicians and other care providers, (5) To cooperate with researchers studying the other hematopoietic failure disorders. All of these efforts are directed toward improving understanding of the care of patients with severe chronic neutropenia.
The Registry benefits patients, their families and the physicians who treat them by providing the most up to date information to them on the natural history of SCN and its treatment options, leading to improved medical care. It is also used to further research to determine the causes of neutropenia.
| Dale, David C (2018) Editorial: myeloid biology issue 2018. Curr Opin Hematol 25:1-2 |
| Dale, David C; Crawford, Jeffrey; Klippel, Zandra et al. (2018) A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer 26:7-20 |
| Xia, Jun; Miller, Christopher A; Baty, Jack et al. (2018) Somatic mutations and clonal hematopoiesis in congenital neutropenia. Blood 131:408-416 |
| Makaryan, Vahagn; Kelley, Merideth L; Fletcher, Breanna et al. (2017) Elastase inhibitors as potential therapies for ELANE-associated neutropenia. J Leukoc Biol 102:1143-1151 |
| Skokowa, Julia; Dale, David C; Touw, Ivo P et al. (2017) Severe congenital neutropenias. Nat Rev Dis Primers 3:17032 |
| Dale, David C (2017) How I manage children with neutropenia. Br J Haematol 178:351-363 |
| Dale, David C (2017) Editorial for myeloid biology 2017. Curr Opin Hematol 24:1-2 |
| Dale, David C; Bolyard, AudreyAnna; Marrero, Tracy et al. (2017) Long-Term Effects of G-CSF Therapy in Cyclic Neutropenia. N Engl J Med 377:2290-2292 |
| Dale, David C; Bolyard, Audrey A (2017) An update on the diagnosis and treatment of chronic idiopathic neutropenia. Curr Opin Hematol 24:46-53 |
| Dale, David C (2016) Editorial: The mysteries of the spleen. J Leukoc Biol 100:249-51 |
Showing the most recent 10 out of 52 publications
